Bionano Genomics is a life sciences instrumentation company which focuses on the genome analysis subspace. Shares of the genetic testing specialist jumped on Tuesday after announcing potential applications of its patented Saphyr optical genome mapping system was announced. Bionano’s system recently discovered structural variants in a person’s genome that may predispose them to severe COVID-19 illness.
This process will help identify individuals who are at high risk to the virus and would help hospitals and research centers understand the factors that exacerbate a person’s symptoms. In addition, Bionano’s Saphyr system can also detect large structural variations for many other diseases and conditions, such as cancer and developmental disorders.
The application of this system will be quite useful in in the long term, far beyond the scope of the current pandemic. The company is currently valued at roughly $2.1 billion after a tremendous Q4 of 2020, gaining over 1,300% since October. BNGO is rising from predicted future earnings and the company is poised for a bullish 2021 assuming trials of their Saphyr OGM system continue to prove fruitful.
eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.
Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
Past performance is not an indication of future results.
Cryptoassets are volatile instruments which can fluctuate widely in a very short timeframe and therefore are not appropriate for all investors. Other than via CFDs, trading cryptoassets is unregulated and therefore is not supervised by any EU regulatory framework.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.